The Urological Oncology group focuses on the study of the genetics and cell biology of urological tumors, primarily metastatic castration-resistant prostate cancer (mCRPC) and the rare disease tuberous sclerosis (TS). The main objective is to identify new therapeutic targets and markers for early detection and disease progression in order to achieve more personalized treatment for patients. Our group studies the impact of the primary cilium—a cellular organelle where the signaling platforms for the Hedgehog, Notch, and WNT pathways, as well as some tyrosine kinase pathways, are located—on tumor progression and TS. To this end, we analyze primary cilia abnormalities in tumors and the consequences of these defects for tumor initiation, progression, and response to treatment in tumor cells, correlating them with disease stage. In our studies, we primarily use in vitro cellular models, advanced imaging techniques, liquid biopsy samples (exosomes and circulating tumor cells), and solid tissue samples from patients.